Subhashis Banerjee

8.1k total citations · 3 hit papers
79 papers, 6.3k citations indexed

About

Subhashis Banerjee is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Subhashis Banerjee has authored 79 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Immunology, 22 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Subhashis Banerjee's work include Psoriasis: Treatment and Pathogenesis (15 papers), Cytokine Signaling Pathways and Interactions (14 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Subhashis Banerjee is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (15 papers), Cytokine Signaling Pathways and Interactions (14 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Subhashis Banerjee collaborates with scholars based in United States, Canada and United Kingdom. Subhashis Banerjee's co-authors include Michael Paskind, Daniel E. Tracey, Robert Kamen, Winnie W. Wong, Thomas P. Burris, Laura A. Solt, George W. Buchman, J N Hansen, Tara Seshadri and Ping Li and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Subhashis Banerjee

75 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock

1995 1.2k citations Ping Li, Hamish Allen et al. Cell profile →
Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN- γ production

1997 1.0k citations Subhashis Banerjee, Michael Paskind et al. profile →
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists

2012 649 citations Laura A. Solt, Yongjun Wang et al. profile →

Peers

Countries citing papers authored by Subhashis Banerjee

Since Specialization

Citations

This map shows the geographic impact of Subhashis Banerjee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Subhashis Banerjee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Subhashis Banerjee more than expected).

Fields of papers citing papers by Subhashis Banerjee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Subhashis Banerjee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Subhashis Banerjee. The network helps show where Subhashis Banerjee may publish in the future.

Co-authorship network of co-authors of Subhashis Banerjee

This figure shows the co-authorship network connecting the top 25 collaborators of Subhashis Banerjee. A scholar is included among the top collaborators of Subhashis Banerjee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Subhashis Banerjee. Subhashis Banerjee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial 2024 ·British Journal of Dermatology ·(unknown), Yangfeng Ding, Ping Wang, Linfeng Li, Weili Pan, Yan Lü, (unknown), Xian Jiang, Ji‐Chen Ho, Shuping Guo, (unknown), Arkendu Chatterjee, (unknown), Subhashis Banerjee	6
2	Traceable mixnets 2024 ·Proceedings on Privacy Enhancing Technologies ·Prashant Agrawal, (unknown), (unknown), (unknown), Subhashis Banerjee	0
3	Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program 2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Richard B. Warren, Howard Sofen, (unknown), C. Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, (unknown), Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt	3
4	Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915 2023 ·European Journal of Medicinal Chemistry ·(unknown), Sadichha Sitaula, Cyrielle Billon, (unknown), (unknown), (unknown), (unknown), Arindam Chatterjee, Kristine Griffett, Subhashis Banerjee, (unknown), (unknown), (unknown), (unknown), Ian Mitchelle S. de Vera, Thomas P. Burris, John K. Walker	4
5	LP-187 Abstract withdrawn 2023 ·SHILAP Revista de lepidopterología ·Marta Mosca, Laurent Arnaud, Anca Askanase, (unknown), Shalabh Singhal, Subhashis Banerjee, (unknown), Jiyoon Choi, Adrian Coles, Brandon Becker, Vibeke Strand	1
6	Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary 2023 ·JAMA Dermatology ·Kim Papp, Kenneth B. Gordon, Bruce Strober, (unknown), Brandon Becker, (unknown), Jennifer L. Beaumont, (unknown), Renata M. Kisa, Andrew Napoli, Subhashis Banerjee, April W. Armstrong	3
7	Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation 2023 ·Journal of Biological Chemistry ·Geetika Aggarwal, Subhashis Banerjee, (unknown), (unknown), (unknown), (unknown), Denise M. Smith, Michael L. Niehoff, (unknown), Ian Mitchelle S. de Vera, Terri L. Petkau, Blair R. Leavitt, Karen Ling, Paymaan Jafar‐Nejad, (unknown), John E. Morley, Susan A. Farr, Paul A. Dutchak, Chantelle F. Sephton, Andrew D. Nguyen	7
8	Adropin transgenesis improves recognition memory in diet-induced obese LDLR-deficient C57BL/6J mice 2021 ·Peptides ·S. P. Ghoshal, Subhashis Banerjee, Jinsong Zhang, Michael L. Niehoff, Susan A. Farr, Andrew A. Butler	4
9	Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis 2021 ·Journal of Allergy and Clinical Immunology ·Ian M. Catlett, Yanhua Hu, Lu Gao, Subhashis Banerjee, Kenneth B. Gordon, James G. Krueger	51
10	Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction 2020 ·Journal of Biological Chemistry ·Subhashis Banerjee, S. P. Ghoshal, Joseph R. Stevens, Kyle S. McCommis, Su Gao, Mauricio Castro‐Sepúlveda, María Luisa Mizgier, C. Giŗardet, (unknown), José E. Galgani, Michael L. Niehoff, Susan A. Farr, Jinsong Zhang, Andrew A. Butler	25
11	Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Kristine Griffett, Lamees Hegazy, Mohamed Elagawany, (unknown), (unknown), Subhashis Banerjee, Thomas P. Burris, Bahaa Elgendy	17
12	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis 2017 ·Annals of the Rheumatic Diseases ·Philip J. Mease, Alice B. Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, Dafna D. Gladman	155
13	Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression 2016 ·PLoS ONE ·Ariadna Amador, Yongjun Wang, Subhashis Banerjee, (unknown), Laura A. Solt, Thomas P. Burris	24
14	Nuclear Receptors and Their Selective Pharmacologic Modulators 2013 ·Pharmacological Reviews ·Thomas P. Burris, Laura A. Solt, (unknown), Christine Crumbley, Subhashis Banerjee, Kristine Griffett, Thomas Lundåsen, Tudor Hughes, Douglas J. Kojetin	217
15	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis 2012 ·Journal of Allergy and Clinical Immunology ·James G. Krueger, Scott Fretzin, Mayte Suárez‐Fariñas, Patrick Haslett, Krista M Phipps, Gregory S. Cameron, Juliet McColm, (unknown), Inna Cueto, (unknown), Subhashis Banerjee, Robert W. Hoffman	300
16	Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbα 2012 ·Bioorganic & Medicinal Chemistry Letters ·Youseung Shin, Romain Noël, Subhashis Banerjee, Douglas J. Kojetin, Xinyi Song, Yuanjun He, Lin Li, Michael D. Cameron, Thomas P. Burris, Theodore M. Kamenecka	17
17	Role of oxidative stress in the promoting activities of PCBs 2007 ·Environmental Toxicology and Pharmacology ·Howard P. Glauert, Job C. Tharappel, Zijing Lu, (unknown), Subhashis Banerjee, (unknown), Eun Y. Lee, Hans‐Joachim Lehmler, Larry W. Robertson, Brett T. Spear	33
18	Caspase-1 Activation of IL-1β and IL-18 Are Essential for Shigella flexneri–Induced Inflammation 2000 ·Immunity ·Philippe Sansonetti, Armelle Phalipon, Josette Arondel, (unknown), Subhashis Banerjee, Shizuo Akira, Kiyoshi Takeda, Arturo Zychlinsky	324
19	Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock breakdown → 1995 ·Cell ·Ping Li, Hamish Allen, Subhashis Banerjee, Simon Franklin, (unknown), (unknown), J. J. McDowell, Michael Paskind, (unknown), Jochen Salfeld, E. Gene Towne, Daniel E. Tracey, Scott Wardwell, Wei Fang, Winnie W. Wong, Robert Kamen, Tara Seshadri	1225
20	The induction of arthritis in mice by the cartilage proteoglycan aggrecan: Roles of CD4+ and CD8+ T cells 1992 ·Cellular Immunology ·Subhashis Banerjee, C Webber, A. Robin Poole	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact